Dr Michael Wang Discusses the Importance of Biosimilars in Cancer Care

Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.
February 18, 2020

Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.

Transcript:
What is your position on biosimilar use inpatients with diffues large B-cell lymphoma? Are you comfortable using biosimilar anticancer therapeutics? 
The concept of biosimilars is very powerful and is totally a useful concept. Our healthcare costs are so high, if we don't use biosimilars, our prices will never go down. We cannot afford it. Also biosimilars, in large part, have very good efficacies. I encourage the idea and also the practice of using biosimilars. I am comfortable using biosimilars all the time. When my institution approves of a biosimilar, I have no problem with using it at all. In fact, I'll use it more than the regular high-priced drug.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.